Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.
FDA approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia.
Patients with advanced metastatic lung cancer treated with atezolizumab, a targeted immunotherapy drug, lived significantly longer and with fewer side effects than those who received docetaxel chemotherapy, according to a study published in The Lancet.
A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.
FDA granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma who had disease progression during or following platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery. “Atezolizumab was granted Priority Review designation based... […]
FDA granted an Orphan Drug Designation to VAL-083 for the treatment of medulloblastoma. The investigational drug candidate, developed by DelMar Pharmaceuticals Inc., previously received an orphan designation for glioblastoma in the U.S. and in Europe. VAL-083 is a first-in-class chemotherapeutic. In more than 40 phase I and II clinical studies sponsored by the NCI, VAL-083... […]
FDA is alerting health care professionals about reports of an increased rate of adverse events, including deaths, in clinical trials with the cancer medicine Zydelig (idelalisib) in combination with other cancer medicines.
ITAI YANAI was named the inaugural director of the Institute for Computational Medicine at NYU Langone Medical Center, effective May 1.
The American Society of Clinical Oncology announced the winners of its highest honors, the Special Awards, to be presented during the 2016 ASCO Annual Meeting in June.
THE V FOUNDATION for Cancer Research and the WWE announced a multi-year partnership to support cancer research nationally through funds raised by Connor’s Cure. The announcement was made at Children’s Hospital of Pittsburgh, where Connor’s Cure was originally established, with representatives from the hospital, the WWE and The V Foundation. In 2014, Connor’s Cure was... […]
